These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 20798652)

  • 1. Development of an interactive model of the burden of future coronary heart disease from an employer perspective.
    Lang K; Korn JR; Simko RJ; Zachry WM; Patel NV; Nair R; Menzin J
    J Occup Environ Med; 2010 Sep; 52(9):851-7. PubMed ID: 20798652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indirect cost of ischemic heart disease to employers.
    Guico-Pabia CJ; Murray JF; Teutsch SM; Wertheimer AI; Berger ML
    Am J Manag Care; 2001 Jan; 7(1):27-34. PubMed ID: 11209448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burden of coronary heart disease on the Iranian oil industry (1999-2000).
    Larijani B; Fakhrzadeh H; Mohaghegh M; Pourebrahim R; Akhlaghi MR
    East Mediterr Health J; 2003; 9(5-6):904-10. PubMed ID: 16450520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower respiratory tract infections: impact on the workplace.
    Birnbaum H; Morley M; Leong S; Greenberg P; Colice G
    Pharmacoeconomics; 2003; 21(10):749-59. PubMed ID: 12828496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic burden and cost determinants of coronary heart disease in rural southwest China: a multilevel analysis.
    Le C; Fang Y; Linxiong W; Shulan Z; Golden AR
    Public Health; 2015 Jan; 129(1):68-73. PubMed ID: 25542739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health benefit costs and absenteeism due to insomnia from the employer's perspective: a retrospective, case-control, database study.
    Kleinman NL; Brook RA; Doan JF; Melkonian AK; Baran RW
    J Clin Psychiatry; 2009 Aug; 70(8):1098-104. PubMed ID: 19758521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing alternative methods for determining the incidence, prevalence, and cost burden of coronary heart disease in a corporate population.
    Beckowski MS; Goyal A; Goetzel RZ; Rinehart CL; Darling KJ; Yarborough CM
    J Occup Environ Med; 2012 Aug; 54(8):1026-38. PubMed ID: 22776806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economic consequences of irritable bowel syndrome: a US employer perspective.
    Leong SA; Barghout V; Birnbaum HG; Thibeault CE; Ben-Hamadi R; Frech F; Ofman JJ
    Arch Intern Med; 2003 Apr; 163(8):929-35. PubMed ID: 12719202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-benefit analysis of Wisconsin's screening, brief intervention, and referral to treatment program: adding the employer's perspective.
    Quanbeck A; Lang K; Enami K; Brown RL
    WMJ; 2010 Feb; 109(1):9-14. PubMed ID: 20942294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing risk factors of coronary heart disease and its risk prediction among Korean adults: the 2001 Korea National Health and Nutrition Examination Survey.
    Ko M; Kim MT; Nam JJ
    Int J Cardiol; 2006 Jun; 110(2):184-90. PubMed ID: 16412525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing total health burden from 2001 to 2009: an employer counter-trend success story and its implications for health care reform.
    Allen H; Rogers WH; Bunn WB; Pikelny DB; Naim AB
    J Occup Environ Med; 2012 Aug; 54(8):904-16. PubMed ID: 22850350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil lymphocyte ratio significantly improves the Framingham risk score in prediction of coronary heart disease mortality: insights from the National Health and Nutrition Examination Survey-III.
    Shah N; Parikh V; Patel N; Patel N; Badheka A; Deshmukh A; Rathod A; Lafferty J
    Int J Cardiol; 2014 Feb; 171(3):390-7. PubMed ID: 24388541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The costs and benefits of enhanced depression care to employers.
    Wang PS; Patrick A; Avorn J; Azocar F; Ludman E; McCulloch J; Simon G; Kessler R
    Arch Gen Psychiatry; 2006 Dec; 63(12):1345-53. PubMed ID: 17146009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic cost and epidemiological characteristics of patients with fibromyalgia claims.
    Robinson RL; Birnbaum HG; Morley MA; Sisitsky T; Greenberg PE; Claxton AJ
    J Rheumatol; 2003 Jun; 30(6):1318-25. PubMed ID: 12784409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depression: a neglected major illness.
    Greenberg PE; Stiglin LE; Finkelstein SN; Berndt ER
    J Clin Psychiatry; 1993 Nov; 54(11):419-24. PubMed ID: 8270584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect cost burden of migraine in the United States.
    Hawkins K; Wang S; Rupnow MF
    J Occup Environ Med; 2007 Apr; 49(4):368-74. PubMed ID: 17426520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tegaserod treatment for IBS: a model of indirect costs.
    Smith DG; Barghout V; Kahler KH
    Am J Manag Care; 2005 Apr; 11(1 Suppl):S43-50. PubMed ID: 15926763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002.
    Keevil JG; Cullen MW; Gangnon R; McBride PE; Stein JH
    Circulation; 2007 Mar; 115(11):1363-70. PubMed ID: 17353444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing behavioral health care: an employer's perspective.
    Davidson BN
    J Clin Psychiatry; 1998; 59 Suppl 2():9-12. PubMed ID: 9559754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic cost of return to work: an employer's perspective.
    Soklaridis S; Cassidy JD; van der Velde G; Tompa E; Hogg-Johnson S
    Work; 2012; 43(3):255-62. PubMed ID: 22927610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.